Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pharmacology|May 8, 2014
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I studyStephan Petersenn, Jens Bollerslev, Ayman M Arafat, et al.
PLOS Digital Health|April 25, 2024
COVID-19 cluster surveillance using exposure data collected from routine contact tracing: The genomic validation of a novel informatics-based approach to outbreak detection in EnglandSimon Packer, Piotr Patrzylas, Iona Smith, et al.
Plos Computational Biology|December 4, 2009
An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1Sergei L Kosakovsky Pond, David Posada, Eric Stawiski, et al.
Clinical Endocrinology|February 19, 2014
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III studyRosario Pivonello, Stephan Petersenn, John Newell-Price, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Human Molecular Genetics|January 10, 2008
Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1Nicholas J Bray, Peter A Holmans, Marianne B van den Bree, et al.
Pituitary|March 27, 2013
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyStephan Petersenn, Andrew J Farrall, Christophe De Block, et al.
BMC Bioinformatics|April 21, 2006
Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression dataLesley Jones, Darlene R Goldstein, Gareth Hughes, et al.
RSC Medicinal Chemistry|March 17, 2025
Development of p300-targeting degraders with enhanced selectivity and onset of degradationGraham P Marsh, Mark S Cooper, Sean Goggins, et al.
Journal of Medicinal Chemistry|December 16, 2022
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for OncologyFrederick W Goldberg, Jason G Kettle, Gillian M Lamont, et al.
Pageof 7